SG11202102105VA - Methods and compositions for treating aging-associated impairments using ccr3-inhibitors - Google Patents
Methods and compositions for treating aging-associated impairments using ccr3-inhibitorsInfo
- Publication number
- SG11202102105VA SG11202102105VA SG11202102105VA SG11202102105VA SG11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA SG 11202102105V A SG11202102105V A SG 11202102105VA
- Authority
- SG
- Singapore
- Prior art keywords
- ccr3
- inhibitors
- compositions
- methods
- treating aging
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737017P | 2018-09-26 | 2018-09-26 | |
PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102105VA true SG11202102105VA (en) | 2021-04-29 |
Family
ID=69953286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102105VA SG11202102105VA (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3856195A4 (en) |
JP (1) | JP2022502441A (en) |
KR (1) | KR20210065950A (en) |
CN (1) | CN112789044A (en) |
AU (1) | AU2019346456A1 (en) |
BR (1) | BR112021004938A2 (en) |
CA (1) | CA3111433A1 (en) |
CL (1) | CL2021000724A1 (en) |
CO (1) | CO2021003713A2 (en) |
EA (1) | EA202190463A1 (en) |
IL (1) | IL281578A (en) |
MA (1) | MA53743A (en) |
MX (1) | MX2021002967A (en) |
SG (1) | SG11202102105VA (en) |
TW (1) | TW202027752A (en) |
WO (1) | WO2020069008A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
EP1996551A2 (en) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |
US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
UA109290C2 (en) * | 2010-10-07 | 2015-08-10 | Common Crystals and Salts of CCR3 Inhibitors | |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
SG11201909207VA (en) * | 2017-04-05 | 2019-11-28 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
KR20190131078A (en) * | 2017-04-05 | 2019-11-25 | 알카헤스트 인코포레이티드 | Methods and compositions for treating aging-related disorders with CCR3-inhibitors |
-
2019
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/en unknown
- 2019-09-25 EA EA202190463A patent/EA202190463A1/en unknown
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/en unknown
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en active Application Filing
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/en active Pending
- 2019-09-25 JP JP2021517342A patent/JP2022502441A/en active Pending
- 2019-09-25 MA MA053743A patent/MA53743A/en unknown
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/en active Pending
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/en not_active Application Discontinuation
- 2019-09-26 TW TW108134938A patent/TW202027752A/en unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/en unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN112789044A (en) | 2021-05-11 |
CL2021000724A1 (en) | 2021-10-15 |
EP3856195A1 (en) | 2021-08-04 |
MA53743A (en) | 2022-01-05 |
WO2020069008A1 (en) | 2020-04-02 |
CO2021003713A2 (en) | 2021-04-08 |
BR112021004938A2 (en) | 2021-06-01 |
EP3856195A4 (en) | 2022-06-22 |
KR20210065950A (en) | 2021-06-04 |
AU2019346456A1 (en) | 2021-04-15 |
IL281578A (en) | 2021-05-31 |
EA202190463A1 (en) | 2021-06-29 |
JP2022502441A (en) | 2022-01-11 |
MX2021002967A (en) | 2021-08-11 |
CA3111433A1 (en) | 2020-04-02 |
TW202027752A (en) | 2020-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269787B (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
HK1248153A1 (en) | Methods and compositions for treating aging-associated impairments | |
IL277079A (en) | Cartyrin compositions and methods for use | |
IL280134A (en) | Anti-cd112r compositions and methods | |
IL278004A (en) | Methods and compositions for treating aging-associated conditions | |
IL285496A (en) | Methods for treating cholestasis | |
IL290840A (en) | Compositions and methods for cd123 modification | |
ZA202101362B (en) | Compositions and methods for treating the eye | |
GB201905559D0 (en) | Composition and method | |
ZA202101342B (en) | Compositions and methods for treating the eye | |
IL285886A (en) | Compositions and methods for treating laminopathies | |
SG11202003261PA (en) | Sanitizing compositions and methods for making and using same | |
SG11202104448WA (en) | Compositions and methods | |
SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
GB201909542D0 (en) | Composition and method | |
IL288440A (en) | Compositions and methods for treating retinopathy | |
GB201817444D0 (en) | Methods and compositions | |
ZA202101361B (en) | Compositions and methods for treating the eye | |
ZA202101360B (en) | Compositions and methods for treating the eye | |
ZA202007183B (en) | Compositions and methods for treating the eye | |
GB201819987D0 (en) | Methods and compositions | |
IL285796A (en) | Methods and compositions for treating | |
IL290325A (en) | Biopharmacuetical compositions and related methods | |
IL277463A (en) | Compositions and methods for treating pruritus | |
IL281578A (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |